Skip to main content
All lobbying filings

VIATRIS INC.

Lobbying for VIATRIS INC

 Filing 1st Quarter - Report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Expenses
$490,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Pennsylvania

Official filing document

 Government bodies contacted 5
  • Centers For Medicare and Medicaid Services (CMS)
  • Commerce, Dept of (DOC)
  • HOUSE OF REPRESENTATIVES
  • Natl Economic Council (NEC)
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 9
  • S 891
    Bipartisan Health Care Act
  • HR 1843
    To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
  • S 1302
    Increasing Transparency in Generic Drug Applications Act
  • HR 4132
    Prescription Information Modernization Act of 2025
  • S 2027
    Prescription Information Modernization Act of 2025
  • S 2658
    Medication Affordability and Patent Integrity Act
  • S 3778
    Carbon Resource Innovation Act
  • S 3841
    Last Sale Valuation Act of 2026
  • S 2296
    National Defense Authorization Act for Fiscal Year 2026
 Lobbying activity 5
Health Issues

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering H.R. 1843 / S. 1302 - Increasing Transparency in Generic Drug Applications Act HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S.2658 - The Medication Affordability and Patent Integrity Act

Copyright/Patent/Trademark

IP Issues related to generic medicines Patent Settlements S 1553, The PREVAIL Act

Trade (domestic/foreign)

Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act

Financial Institutions/Investments/Securities

Policy related to corporate governance

Defense

S.2296 National Defense Authorization Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem